NCT01985295 - Combined Modality Treatment of Sarcomas of the Extremities | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

August 31, 2014

Study Completion Date

November 30, 2014

Conditions

Sarcoma,Soft Tissue

Interventions

DRUG

pazopanib

A dose escalation trial of Pazopanib, starting at 400mg daily, orally in combination with the standard 25 x 2Gy preoperative radiotherapy in newly diagnosed extremity sarcoma patients. Dose of pazopanib will be escalated via 600mg to maximally 800mg. Overall treatment time of pazopanib is 40 days.

Trial Locations (1)

1066CX

The Netherlands Cancer Institute, Amsterdam